{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-125073","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.152235+00:00","generated_at":"2026-06-03T04:14:20.069967+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MiMedx Q1 net sales $85M (+18% YoY); GAAP net income $9M; Adj. EBITDA $19M (22% margin)","bullets":["Net sales $85M, up 18% YoY; gross margin improved to 84.7% from 82.7%.","GAAP net income $9M vs loss of $5M in prior year; Adjusted EBITDA $19M (22% margin) vs $5.5M (7.7%).","Cash $48M at March 31, down from $82M at Dec 31, due to repaying $30M revolver and $5M TELA Bio payment.","Signed distribution agreement with Regenity Biosciences for 510(k)-cleared collagen xenograft; launch expected later in 2024.","Appointed two new independent directors; launched MIMEDX Connect online ordering platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-125073","json":"https://secwatch.observer/filing/0001193125-24-125073.json","markdown":"https://secwatch.observer/filing/0001193125-24-125073.md","text":"https://secwatch.observer/filing/0001193125-24-125073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000119312524125073/0001193125-24-125073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000119312524125073/d832294d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:14:20.069967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"515e88eee100980d588e39e86f612afa8aa8fe96","claim":"MIMEDX GROUP, INC. reported first quarter ended March 31, 2024 results: revenue Net Sales of $85 Million, net income GAAP Net Income was $9 Million.","evidence_excerpt":"MIMEDX Announces First Quarter 2024 Operating and Financial Results Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1376339/000119312524125073/0001193125-24-125073-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"Net Sales of $85 Million"},{"label":"Net income","value":"GAAP Net Income was $9 Million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}